Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to -$1.4 million.

  • Ocular Therapeutix's Change in Account Payables fell 130803.57% to -$1.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$887000.0, marking a year-over-year decrease of 17893.08%. This contributed to the annual value of -$887000.0 for FY2025, which is 17893.08% down from last year.
  • According to the latest figures from Q4 2025, Ocular Therapeutix's Change in Account Payables is -$1.4 million, which was down 130803.57% from -$1.3 million recorded in Q3 2025.
  • Ocular Therapeutix's Change in Account Payables' 5-year high stood at $1.7 million during Q2 2025, with a 5-year trough of -$2.4 million in Q2 2024.
  • Moreover, its 5-year median value for Change in Account Payables was $211000.0 (2021), whereas its average is $27650.0.
  • Its Change in Account Payables has fluctuated over the past 5 years, first skyrocketed by 74533.9% in 2021, then crashed by 130803.57% in 2025.
  • Over the past 5 years, Ocular Therapeutix's Change in Account Payables (Quarter) stood at $366000.0 in 2021, then tumbled by 406.56% to -$1.1 million in 2022, then soared by 158.47% to $656000.0 in 2023, then tumbled by 82.93% to $112000.0 in 2024, then plummeted by 1308.04% to -$1.4 million in 2025.
  • Its last three reported values are -$1.4 million in Q4 2025, -$1.3 million for Q3 2025, and $1.7 million during Q2 2025.